BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32196772)

  • 1. Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial.
    Salmivuori M; Grönroos M; Tani T; Pölönen I; Räsänen J; Annala L; Snellman E; Neittaanmäki N
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2781-2788. PubMed ID: 32196772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: A systematic review and meta-analysis.
    Wang BC; Fu C; Qin L; Zeng XY; Liu Q
    Photodiagnosis Photodyn Ther; 2020 Mar; 29():101667. PubMed ID: 31978564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
    Kuijpers DI; Thissen MR; Thissen CA; Neumann MH
    J Drugs Dermatol; 2006; 5(7):642-5. PubMed ID: 16865869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
    Surrenti T; De Angelis L; Di Cesare A; Fargnoli MC; Peris K
    Eur J Dermatol; 2007; 17(5):412-5. PubMed ID: 17673385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy with topical methyl- and hexylaminolevulinate for prophylaxis and treatment of UV-induced SCC in hairless mice.
    Togsverd-Bo K; Lerche CM; Poulsen T; Wulf HC; Haedersdal M
    Exp Dermatol; 2010 Aug; 19(8):e166-72. PubMed ID: 20100196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin.
    Middelburg TA; de Bruijn HS; van der Ploeg-van den Heuvel A; Neumann HA; Robinson DJ
    Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):703-9. PubMed ID: 24284130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate.
    Neittaanmäki-Perttu N; Karppinen TT; Grönroos M; Tani TT; Snellman E
    Br J Dermatol; 2014 Nov; 171(5):1172-80. PubMed ID: 25109244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of photodynamic therapy with amino-5-laevulinate nanoemulsion versus methyl-5-aminolaevulinate for actinic keratosis: A meta-analysis.
    Fu C; Kuang BH; Qin L; Zeng XY; Wang BC
    Photodiagnosis Photodyn Ther; 2019 Sep; 27():408-414. PubMed ID: 31310826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-aminolaevulinic acid nanoemulsion is more effective than methyl-5-aminolaevulinate in daylight photodynamic therapy for actinic keratosis: a nonsponsored randomized double-blind multicentre trial.
    Räsänen JE; Neittaanmäki N; Ylitalo L; Hagman J; Rissanen P; Ylianttila L; Salmivuori M; Snellman E; Grönroos M
    Br J Dermatol; 2019 Aug; 181(2):265-274. PubMed ID: 30329163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.
    Morton CA; Dominicus R; Radny P; Dirschka T; Hauschild A; Reinhold U; Aschoff R; Ulrich M; Keohane S; Ekanayake-Bohlig S; Ibbotson S; Ostendorf R; Berking C; Gröne D; Schulze HJ; Ockenfels HM; Jasnoch V; Kurzen H; Sebastian M; Stege H; Staubach P; Gupta G; Hübinger F; Ziabreva I; Schmitz B; Gertzmann A; Lübbert H; Szeimies RM
    Br J Dermatol; 2018 Aug; 179(2):309-319. PubMed ID: 29432644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20% versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma.
    van Delft LCJ; Nelemans PJ; Kessels JPHM; Kreukels H; Roozeboom MH; de Rooij MJM; Mosterd K; de Haas ERM; Kelleners-Smeets NWJ
    Dermatology; 2022; 238(6):1044-1049. PubMed ID: 35598594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up.
    Gómez C; Cobos P; Alberdi E
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102176. PubMed ID: 33429099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
    Foley P; Freeman M; Menter A; Siller G; El-Azhary RA; Gebauer K; Lowe NJ; Jarratt MT; Murrell DF; Rich P; Pariser DM; Oseroff AR; Barnetson R; Anderson C; Kossard S; Gibson LE; Tope WD
    Int J Dermatol; 2009 Nov; 48(11):1236-45. PubMed ID: 20064185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
    Rhodes LE; de Rie MA; Leifsdottir R; Yu RC; Bachmann I; Goulden V; Wong GA; Richard MA; Anstey A; Wolf P
    Arch Dermatol; 2007 Sep; 143(9):1131-6. PubMed ID: 17875873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial.
    Choi SH; Kim KH; Song KH
    J Eur Acad Dermatol Venereol; 2016 May; 30(5):783-8. PubMed ID: 26551044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
    Caekelbergh K; Nikkels AF; Leroy B; Verhaeghe E; Lamotte M; Vincent R
    J Drugs Dermatol; 2009 Nov; 8(11):992-6. PubMed ID: 19894366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
    Tyrrell JS; Campbell SM; Curnow A
    Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
    Szeimies RM; Ibbotson S; Murrell DF; Rubel D; Frambach Y; de Berker D; Dummer R; Kerrouche N; Villemagne H;
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1302-11. PubMed ID: 18624836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.
    Rhodes LE; de Rie M; Enström Y; Groves R; Morken T; Goulden V; Wong GA; Grob JJ; Varma S; Wolf P
    Arch Dermatol; 2004 Jan; 140(1):17-23. PubMed ID: 14732655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.